Kornimate/medical-research-clean huggingface dataset:
adjuvant dabrafenib and trametinib treatment in patients with completely resected high-risk stage iii melanoma.

Conditions: Melanoma

Summary: non-interventional (observational) cohort prospective real life study with primary and secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in patients with completely resected high-risk stage iii (stage iiia \[lymph node \> 1mm\], iiib, iiic and iiid according to ajcc 8th edition) melanoma in turkey.

the prospective registration of completely resected high-risk stage iii melanoma patients treated with dabrafenib and trametinib in the adjuvant setting will be based on collaboration with centers of excellence on melanoma patients treatment. pre-identified centers (up to 12) considered as the most advanced according to their knowledge and experience, will take part in the patients recruitment.

Eligibility criteria:
inclusion criteria: * patients with complete surgical resection of histologically confirmed ajcc (8th edition) clinical stage iii (stage iiia \[lymph node \> 1mm\],, iiib, iiic, iiid) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study; * v600e mutation-positive cutaneous melanoma; * ≥ 18 years of age; * written informed consent signed. exclusion criteria: * lack of basic demographic and staging data. * current active participation in an interventional clinical trial for treatment of melanoma. * pregnancy or breastfeeding women. * current primary diagnosis of a cancer other than melanoma, that requires systemic or other treatment.

Keywords: melanoma stage iii melanoma braf v600e mutation dabrafenib trametinib turkey
a transoral retropterygoid approach to resect recurrent nasopharyngeal carcinoma

Conditions: Recurrent Nasopharyngeal Carcinoma

Summary: this is a a prospective, single-arm, and exploratory study of endoscopic resection of recurrent nasopharyngeal carcinoma via transoral retropterygoid approach.

the present study explored a novel transoral retropterygoid approach to resect recurrent nasopharyngeal carcinoma, aiming to investigate the effectiveness of this novel approach in the treatment of recurrent nasopharyngeal carcinoma. the primary end point was the margin-negative (r0) resection rate.

Eligibility criteria:
inclusion criteria: * pathology or radiography confirmed recurrent nasopharyngeal carcinoma. * ajcc rt2-t4 which can be surgically removed. * no distant metastasis. * aged 18 or more than 18 years old. * with or without lymph node metastasis, which can be surgically removed. * no severe restricted mouth opening, and oral approach eligible. * sufficient organ function. * with signed informed consent. * ecog score 0-2, and general physical condition can tolerate general anesthesia surgery. exclusion criteria: * primary nasopharyngeal carcinoma * the patient has surgical contraindications: such as severe cardiopulmonary disease and coagulation dysfunction, etc. * the patient has any situation that may hinder study compliance or the safety during the study period. * suffer from uncontrolled disease which could interfere with treatment. * uncontrolled active infection. * pregnant or breastfeeding women * there are some other situations that are not suitable for entry into the study.
development and evaluation of an artificial intelligence tool for colposcopy assistance

Conditions: Cervical Cancer; HSIL; LSIL; Cervical Ectropion

Summary: project aiming to develop an algorithm to help the interpretation of colposcopy images, then to evaluate the effectiveness of this algorithm by using it on new cases and comparing the results obtained to the impression of expert clinicians

due to the increase in the number of colposcopies following changes in recommendations regarding cervical cancer screening, the investigators wondered about the benefit of assistance provided by the computer tool. several teams have already developed algorithms to aid in the interpretation of colposcopy, but the studies were carried out in countries that do not have the colposcopic expertise of french practitioners, and no algorithm has has demonstrated its effectiveness to our knowledge, the different results being inhomogeneous. the investigators therefore wanted to develop an algorithm to aid colposcopy based on clinical cases carried out by practitioners considered experts, then evaluate its effectiveness. the investigators manually collect data concerning adult patients who underwent colposcopy by an expert doctor at la pitié-salpêtrière between september 1, 2022 and december 31, 2023, for whom the photographs of the colposcopic examination (without staining, after acid acetic and after lugol) are available and usable and for which the clinical context is known. if a biopsy has been performed, the histological result is considered the gold standard. if this is not the case (normal and satisfactory colposcopy), the investigators consider by default that the histology is normal. the investigators excluded all patients for whom photographs were of poor quality or unavailable. development of the algorithm with the help of a computer science student, aiming to answer the following 2 questions: * assumed histological result * localization of the targeted biopsy if necessary evaluation of the algorithm: use of the algorithm for new cases, then comparison of the results obtained with the response given by expert clinicians (reading of images by 2 colposcopists). the aim will be to highlight the non-inferiority of the algorithm.

Eligibility criteria:
inclusion criteria: 1. adult patients who underwent colposcopy with directed biopsies at la pitié-salpêtrière between september 1, 2022 and december 31, 2023 2. known clinical context (why the patient underwent colposcopy) 3. histological results of cervical biopsies (+/- conization or even hysterectomy) known 4. images available (photographs of the cervix without preparation, after application of acetic acid and after application of lugol) 5. informed of the study and not opposing the use of their data exclusion criteria: * patients who do not speak french

Keywords: artificial intelligence colposcopy machine learning algorithm papillomavirus cervical cancer
treatment of venous malformation

Conditions: Venous Malformation

Summary: vascular malformations are birth defects that happen when different stages of angiogenesis shut down. 44 - 64% of all vascular malformations are venous malformations (vms). sclerotherapy is the first treatment line for vms. it acts by getting rid of the vascular endothelial cells in the lesion. one of the most common and well researched sclerosing agents for vms is polidocanol, which is a popular counterpart for concentrated ethanol.


Eligibility criteria:
inclusion criteria: * patients diagnosed with venous malformation of both genders and age above one year. exclusion criteria: * age below one year. * patients had any other vascular malformations. * indication for contrast material or alcohol and polidocanol injection. * unfit for general anesthesia. 5) pregnancy. 6) skin infection, inflammation, and ulcers. * pulmonary embolism. * acute ischemia, and acute dvt.
motion correction of positron emission tomography (pet) data using amplitude gating

Conditions: Lung Cancer

Summary: objectives: evaluation of an amplitude based gated positron emission tomography (pet) data acquisition system for all ge discovery positron emission tomography/ computed tomography (pet/ct) scanners.

routine pet/ct scans are taken while patients are breathing normally. the motions made by breathing can reduce the image quality of the scan. minimizing the effects of this motion by taking the images and processing the scans differently may improve the image quality. the pet/ct scan: if you agree to take part in this study, an elastic belt will be placed around your lower chest/upper abdomen before your routine pet/ct scan. this belt is used to track your breathing motion. this information will be used to help process the scan. your pet/ct scan will be performed as usual. during the scan, researchers will focus on your lower chest/upper abdomen (areas that experience breathing motion). having to focus on this area might extend the scan by up to 10 minutes. the additional scan time will not increase your radiation exposure since only pet scanning will be performed. length of study: your participation on this study will be complete when your scheduled pet/ct scan is complete. this is an investigational study. the imaging focused on your lower chest/upper abdomen during the scan is investigational. up to 26 patients will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. patients with lung or liver lesions measuring 0.5-2cm in diameter will be considered. 2. patients that are scheduled to be imaged in the pet/ct suite at the mays building will only be considered. exclusion criteria: 1. pediatric patients (younger than 18 years) will be excluded. 2. patients that cannot tolerate being scanned for an additional 10 minutes with arms above their head will be excluded.

Keywords: lung lung cancer non-small cell lung cancer nsclc motion correction pet/ct scan pet positron emission tomography ct computed tomography amplitude gating
the safety and immunogenicity evaluation of live attenuated influenza vaccine

Conditions: Influenza Prevention

Summary: live attenuated freeze-dried influenza vaccine has been licensed for use in 2020 (approval no.s20200002), the sponsor of this research submitted an new application for non freeze-dried live attenuated influenza vaccine in 2021. the main objective of phase ⅰ trail is to evaluate the safety of lavi(non freeze-dried). the secondary objective is to evaluate the immunogenicity of lavi(non freeze-dried).

totally 160 health people aged 3-59 years old will be divided into two age group, containing 80 in 18-59 years old and 80 in 3-19 years old. all subjects will receive vaccination either lavi or placebo in a ratio of 3:1. all subjects will be collected any adverse events within 30 days and any serious adverse events within 6 months for safety evaluation. all subjects will be collected blood sample and nasopharyngeal swab for immunogenicity evaluation.

Eligibility criteria:
inclusion criteria: * healthy volunteers aged in 3-59 years old. * had not received vaccination of influenza vaccine in the past half of years. * had not infected with influenza virus. * this trail has been agreed by volunteers or his/her legal guardian. * volunteers or his/her legal guardian will fellow this trail protocol. exclusion criteria: * people from 18-59 age group with abnormal laboratory index. (slight abnormality is except if judged with no clinical significance by doctors.) * people with fever before vaccination, temperature higher than 37.0 ℃ * females in suckling period, pregnancy (pregnancy test positive) or prepared to be pregnant * people given whole blood, plasma or immunoglobulin therapy within 3 months before vaccination * according to judgement of researchers, the subjects have any other factors that are not appropriate for this clinical trials. * acute infectious disease or acute attack of chronic disease before inoculation * people get any vaccine within 14 days before the trial. * people in immune deficiency or diagnosed with congenital or acquired immunodeficiency, people with immunosuppressive therapy in the past six months. * people with epilepsy or a history of mental illness

Keywords: safety immunogenicity live attenuated influenza vaccine
preop covid testing patterns

Conditions: COVID-19

Summary: this study is an investigation of preoperative asymptomatic covid screening nationwide. the hypothesis is that because these tests are performed without reference to pretest probability of covid-19 disease, unlike tests based on symptoms or close contact with infected individuals, these studies may represent a more unbiased sample of the local population prevalence of asymptomatic covid disease burden.

study will gather publicly reported, aggregated statistics on positive covid tests over time and across geographically diverse parts of the united states, summarized weekly, from the onset of the pandemic in spring 2020 to the present time. study will also gather contemporaneous data on weekly community covid cases diagnosed, local positive test percentage, hospital admissions and icu admissions for covid-19, and deaths from covid 19. similar data will be obtained from a coalition of approximately 20 academic medical centers from around the united states, with wake forest school of medicine, department of anesthesiology serving as the coordinating center. no individual patient information will be collected. aggregated testing data, hospital disease burden, and local disease prevalence are all publicly reported. data will analyzed as interrupted time series.

Eligibility criteria:
inclusion criteria: * having preoperative asymptomatic covid testing * \> or = 18 years of age exclusion criteria: * none

Keywords: testing, preoperative
changing talk to reduce resistiveness to care

Conditions: Dementia

Summary: the investigators are interested in reducing problem behaviors of nursing home residents with dementia that make providing care difficult. the investigators call these behaviors resistiveness to care. previous research has found that resistiveness to care occurs more frequently when staff use certain types of communication. an inservice program will be provided to all nursing staff in your nursing home to teach staff about communication practices to reduce resistiveness to care. the research study will see whether changing communication will reduce resident resistiveness to care. if effective, the communication training may then be used to improve care in other facilities. by doing this study, researchers hope to learn if changing communication practices will reduce resistiveness to care in nursing home residents with dementia.


Eligibility criteria:
staff:inclusion criteria for cnas are: * age 18 years old or greater (age of legal consent in kansas and missouri), signed informed consent, * permanent employment in the nh, * primary assignment to a specified unit, * and english speaking * staff must have been assigned to care for the resident at least twice weekly in the past month (documented in nh staffing records). this will assure that staff-resident dyads have established relationships and will control effects of variability in contact between dyads during days when data are not being collected. resident inclusion criteria are: * a diagnosis of alzheimer's disease or related dementia documented in their medical records, * documentation of daily rtc over the past week, * and ability to hear staff communication (from the most recent mds). exclusion criteria for cnas include: * non-english speaking, * temporary employment, -and age under 18 years. * if more than one cna volunteers as a partner for a participating resident, a random selection will be made to determine which cna will participate. small variations in contact between staff and residents in dyads are anticipated due to pmma policies for consistent cna assignment to neighborhoods. therefore dyads will have repeated contacts. exclusion criteria for residents include: * diagnosis with huntington's disease, * alcohol-related dementias, * schizophrenia, * manic-depressive disorder, * deafness, * and mental retardation.

Keywords: nursing staff residents
epidemiology of cardiotoxicity in children with cancer

Conditions: Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive; Death, Sudden, Cardiac; Heart Failure

Summary: to provide a comprehensive analysis of risk factors for the development of clinical cardiotoxicities in over 6,000 children with cancer who had been treated on standardized protocols involving the use of anthracyclines alone or in combination with other potentially cardiotoxic therapies or with no use of anthracycline therapy.

design narrative: the data were analyzed to estimate the incidence of clinical cardiotoxicity as measured by sudden death, congestive heart failure, or discontinuation of therapy based on cardiac function. evaluation of patient characteristics (age, anemia) and treatment factors such as drug, dose level, dosing schedule, exposure to irradiation and/or cyclophosphamide identified groups at particularly high risk for development of clinical cardiotoxicity and provided estimates of this risk for future treatment planning. such estimates of high risk groups should make possible future trials to test the feasibility of using cardioprotectors or alternate dosing schedules to prevent cardiotoxicity. the incidence of clinical cardiotoxicity was calculated using kaplan- meier estimates as a function of total cumulative anthracycline dose and also as a function of the time since the end of treatment stratified by dose levels. the estimates were stratified by exposure to cyclophosphamide and radiation therapy. multivariate methods were used to evaluate the prognostic significance of selected patient characteristics and treatment parameters and to provide estimates of the relative risk of each variable. the method of recursive partitioning was used to identify subpopulations at elevated risk for clinical cardiotoxicity. the data and analytic techniques were accessible through sas data sets and procedures available to the study at the pediatric oncology group (pog) statistical office. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
early markers of radiation-induced cardiac injury in hodgkin lymphoma treated with radiation therapy

Conditions: Hodgkin's Lymphoma

Summary: the purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of hodgkin's lymphoma.


Eligibility criteria:
inclusion criteria: * completed radiation and chemotherapy treatment for hodgkin lymphoma involving the mediastinum. * patient must be ≥ 18 years at time of consent. exclusion criteria: * pregnant women at time of cardiac mri * contraindications to cardiac mri (contrast allergy, metal implants, medical devices) * glomerular filtration rate (gfr) \< 30, unless approved by radiologist (uf health jacksonville radiology policy: administration of gadolinium-based contrast agents).

Keywords: radiation cardiac hodgkin's lymphoma
cardiac resynchronization therapy efficacy enhancements

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to demonstrate that the amount of effective crt (cardiac resynchronization therapy) pacing during af (atrial fibrillation) when cafrplus (conducted af response plus) is applied is not inferior to the amount of effective crt pacing during af when cafr (conducted af response) is applied.

the crtee study is an ide, prospective, multi-center, randomized, controlled, crossover clinical study, conducted worldwide and designed to demonstrate that the amount of effective crt pacing during af (atrial fibrillation) when cafrplus (conducted af response plus) is applied is not inferior to the amount of effective crt pacing during af when cafr (conducted af response) is applied. the study will be conducted at up to 30 centers located in the united states, europe and middle east and africa (mea).

Eligibility criteria:
inclusion criteria: * subject is willing to sign and date the study patient informed consent form. * subject is at least 18 years of age (or older, if required by local law). * subject is expected to remain available after enrollment to complete follow-up visits in both arms of the study * subject has had a medtronic viva or brava crt-d device implanted at least 30 days prior to enrollment. * subject has history of af burden, of at least 6 days of at least 4 hours of af over any 4 week period within the last 90 days as documented in device diagnostic data or if subject has no atrial lead (therefore no device diagnostic data) but clinical evidence of high af burden. * subject has demonstrated history of being able to complete left ventricular capture management (lvcm) documented in device data. * subject has a documented % v pacing during af of less than or equal to 97% within 90 days prior to enrollment or within 10 days after enrollment. exclusion criteria: * subject has undergone av node ablation for treatment of af. * subject has complete or 3rd degree av block. * subject has had an mi within 30 days. * subject has medical conditions that limit study participation (per physician discretion). * subject is enrolled in one or more concurrent studies that could confound the study results as determined by medtronic. * subject has a limited life expectancy for non-cardiac causes that would not allow completion of the study. * subject is pregnant (in the us, all women of child-bearing potential must undergo a pregnancy test within seven days prior to crtee download). * subject meets the exclusion criteria required by local law.
dynamic follow-up of symptoms based on patient-reported outcomes in immunotherapy for esophageal cancer: a prospective multicentre cohort study (spring)

Conditions: Esophageal Cancer; Patient-reported Outcomes; Immunotherapy

Summary: immunotherapy shows satisfactory effectiveness and safety in patients with esophageal cancer. immunotherapy-based regimens have a better survival benefit compared to previous chemotherapy and radiotherapy. patient-reported outcomes (pro) provide a reliable assessment of patients' functional status during treatment. however, the spectrum of symptoms in esophageal cancer patients receiving immunotherapy is uncertain, and there are no studies applying the symptom bank based on pro to the immunotherapy model for esophageal cancer. in this prospective study, the investigators aimed to preliminarily screen for symptoms associated with immunotherapy for esophageal cancer through a systematic literature review and expert evaluation, and build a symptom item bank for esophageal cancer patients receiving immunotherapy. adverse symptoms in esophageal cancer patients treated with immunotherapy were collected prospectively. the distribution and severity of the symptoms, as well as the trajectory of symptom change were further analyzed to demonstrate the validity and reliability of the symptom item bank. it would refine the spectrum of symptoms for esophageal cancer patients receiving immunotherapy and provide a foundation for assessing the specific symptom burden in patients with esophageal cancer receiving immunotherapy regimens.


Eligibility criteria:
inclusion criteria: * pathologically confirmed resectable, locally advanced, advanced metastatic esophageal cancer * having received or undergoing an immunotherapy-based treatment regimen * age 18-75 years * ecog ps of 0-2 * adequate organ function * life expectancy \> 6 months * participants are fully informed about the whole study and are willing to sign the informed consent exclusion criteria: * absence of immunotherapy regimen, or recieving radiotherapy. * presence of primary tumours elsewhere, such as gastric cancer, lung cancer or cervical cancer * severe organ function deterioration and intolerance to immunotherapy * pregnant or breast-feeding women * previous autoimmune disease * any other conditions that may affect patients' safety and compliance * psychological, family, social and other factors leading to inability to inform consent

Keywords: esophageal cancer immunotherapy patient-reported outcomes symptom item bank